Valuation: Cogent Biosciences, Inc.

Market Cap 5.38B 4.78B 4.46B 4.07B 7.68B 518B 7.75B 54.03B 20.94B 265B 20.21B 19.78B 849B P/E 2026 *
-13.8x
P/E 2027 * -29.6x
Enterprise Value 5.25B 4.67B 4.36B 3.97B 7.49B 505B 7.56B 52.73B 20.43B 258B 19.73B 19.3B 829B EV / Sales 2026 *
877x
EV / Sales 2027 * 17.7x
Free-Float
99.51%
Yield 2026 *
-
Yield 2027 * -
1 day-1.80%
1 week-3.99%
Current month-3.12%
1 month-10.27%
3 months-19.82%
6 months-11.90%
Current year-12.67%
1 week 30.86
Extreme 30.855
32.76
1 month 30.35
Extreme 30.3501
35.75
Current year 30.35
Extreme 30.3501
43.39
1 year 13.78
Extreme 13.78
43.73
3 years 3.67
Extreme 3.67
43.73
5 years 3.67
Extreme 3.67
43.73
10 years 3.67
Extreme 3.67
43.73
Manager TitleAgeSince
Chief Executive Officer 50 22/10/2020
Director of Finance/CFO 45 31/05/2018
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 68 31/01/2018
Director/Board Member 74 25/07/2019
Director/Board Member 59 25/07/2019
Date Insider Type Main position Quantity % Market Cap. Importance
27/08/26 Exercice

Director

136,530 0.0787%
01/07/26 Free

Director

627 0.0004%
09/06/26 Free

Director

17,901 0.0105%
Change 5-day change 1-year change 3-year change Capi.($)
-1.80%-3.99%+110.31%+224.82% 5.48B
+4.16%+3.04%+49.37%+94.17% 74.41B
-3.11%-3.53%+21.92%+74.60% 59.26B
+0.89%-0.63%+4.28%+34.51% 47.14B
-0.96%-4.50%+26.36%+33.18% 42.91B
+0.36%+0.81%+352.17%+689.61% 44.13B
-0.20%-0.77%+3.74%+100.60% 40.79B
-0.54%+2.93%+9.31%+50.41% 30.77B
-2.68%+2.92%+29.63%+19.50% 29.31B
+2.33%-5.69%-27.28%+338.00% 23.71B
Average -0.15%-1.11%+57.98%+165.94% 39.79B
Weighted average by Cap. +0.21%-1.02%+58.08%+151.75%

Financials

2026 *2027 *
Net sales 5.99M 5.32M 4.97M 4.53M 8.54M 576M 8.62M 60.1M 23.29M 294M 22.48M 22M 945M 293M 260M 243M 221M 417M 28.15B 421M 2.94B 1.14B 14.39B 1.1B 1.08B 46.18B
Net income -399M -354M -331M -302M -569M -38.35B -574M -4B -1.55B -19.61B -1.5B -1.47B -62.92B -202M -180M -168M -153M -288M -19.45B -291M -2.03B -787M -9.94B -760M -743M -31.91B
Net Debt -130M -115M -108M -98M -185M -12.46B -187M -1.3B -504M -6.37B -487M -476M -20.45B -206M -183M -171M -156M -294M -19.81B -297M -2.07B -801M -10.13B -774M -757M -32.51B
Logo Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision therapies for genetically defined diseases. Its approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious and rare disease caused by unchecked proliferation of mast cells. The Company has on-going Phase I studies of its CNS-penetrant, selective mutant ErbB2 inhibitor and its potential best-in-class, wild-type-sparing, PI3Ka inhibitor. In addition, the Company’s research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in KRAS and JAK2.
Employees
258
Date Price Change Volume
02/10/26 US$31.02 -1.80% 1,172,132
01/10/26 US$31.59 -1.34% 1,698,630
30/09/26 US$32.02 +1.14% 1,960,172
29/09/26 US$31.66 -0.63% 1,704,731
28/09/26 US$31.86 -1.39% 2,212,923
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
31.02USD
Average target price
55.82USD
Spread / Average Target
+79.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COGT Stock